IMIM - Institut Hospital del Mar d'Investigacions Mèdiques IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

News

  • 11/01/2016 - Press release

    New genes formed continuously allowing acquisition of novel functions during evolution

    Research just published in the journal Plos Genetics has found that gaining new genes during evolution is a much more frequent event than previously thought. It has been seen that there are hundreds of genes that might be unique to humans, and something similar occurs in chimpanzees. Some of these genes will be useful for the organism in question and the rest will disappear in time. The work was led by Mar Albà, an ICREA researcher at the Mar Institute of Medical Research (IMIM) and Jorge Ruiz-Orera, from the same group, together with researchers from Pompeu Fabra University (UPF) and the Centre for Genomic Regulation (CRG). For some time it was thought that all new genes originated from other genes, for example, from duplications of already existing genes. But recently it has been seen that some, the so-called de novo genes, originate in genomic regions that previously contained none. According to Mar Albà “This work shows that the formation of DNA motifs, through the accumulation of random mutations, would have been a determining factor in the emergence of new genes.” DNA motifs are elements that activate gene expression.

    Més informació "New genes formed continuously allowing acquisition of novel functions during evolution"

  • 22/12/2015 - Press release

    Using telemedicine to treat heart failure reduces clinical complications and decreases the cost by over 3500 euros per patient

    A study by the Cardiology Service's Heart Failure Unit at the Hospital del Mar and IMIM (Hospital del Mar Medical Research Institute) has demonstrated that patients with chronic heart failure (HF) who are telephonically monitored have better results with regard to relapse and rehospitalisation than patients that receive conventional on-site follow-up. For six months the researchers used an electronic platform to analyse the evolution of a group of telephonically monitored patients, who used videoconferencing to communicate with the healthcare team. According to the study published in the Journal of Telemedicine and Telecare, the group being monitored using telemedicine also involved a 3,546 euro reduction in average cost per patient compared to the control group, over the six months of follow-up.

    Més informació "Using telemedicine to treat heart failure reduces clinical complications and decreases the cost by over 3500 euros per patient"

  • 03/11/2015 - Press release

    New computational approach to predicting adverse drug reactions with higher confidence

    A new integrated computational method helps predicting adverse drug reaction—which are often lethal—more reliably than with traditional computing methods. This improved ability to foresee the possible adverse effects of drugs may entail saving many lives in the future. The study that is being conducted by researchers from IMIM (Hospital del Mar Medical Research Institute), Pompeu Fabra University, and the company Chemotargets, within the framework of the European eTOX project, was chosen for the cover of the journalChemical Research in Toxicology. Most computer tools employed today to detect possible adverse effects of compounds that are candidates for new medicines are based on detecting labile fragments in the drug's structure. These fragments can potentially transform to form reactive metabolites, which can have toxic properties. This is what is known as idiosyncratic toxicity and is a big headache for the pharmaceutical industry, as it tends to be detected in late development stages of the drug and even when it is already on the market, often causing the drug to be withdrawn.

    Més informació "New computational approach to predicting adverse drug reactions with higher confidence"

  • 23/10/2014 - Press release

    A new therapeutic target identified for the most widespread cutaneous lymphoma

    Researchers at the Hospital del Mar have discovered one of the key mechanisms in the development and progression of mycosis fungoide, a type of cancer originating in the lymphoid cells that develops initially on the skin. The study, published in the Journal of Investigative Dermatology, was co-led by Fernando Gallardo, a dermatologist at the Hospital del Mar and a researcher in the translational research group on haematopoietic malignancies at the Hospital del Mar Medical Research Institute (IMIM); Luis Espinosa and Anna Bigas from the IMIM Cancer Stem Cells Laboratory; Juan Sandoval, researcher at the La Fe Research Institute (IISlaFe); and Ángel Diaz, researcher at the Bellvitge Biomedical Research Institute (IDIBELL). The project was conducted with a series of skin samples from patients with mycosis fungoide in tumour phase and led to the identification of the miR-200C molecule as a possible therapeutic target for designing future treatments for this disease.

    Més informació "A new therapeutic target identified for the most widespread cutaneous lymphoma"

  • 14/10/2015 - Press release

    A step forward in obtaining blood stem cells in laboratory

    An international study led by researchers from IMIM (Hospital del Mar Medical Research Institute) published in the journal Nature Communications has revealed that the intensity or efficiency of the activation of a protein called Notch, which is involved in the different phases of embryonic development, determines the fate of cells, i.e. if cells will form the aorta artery or blood (hematopoietic) stem cells. For artery cells, many Notch molecules need to be activated, whereas for hematopoietic cells many fewer are needed. According to Dr. Anna Bigas, the coordinator of the group on stem cells and cancer at IMIM “to reach these levels of activation, we have proven that there is a competition between two proteins that activate the Notch molecule, i.e. between two ligands, in a way that one limits the activation generated by the other to form hematopoietic stem cells”. Until now it was known, thanks to the studies conducted by this same group and others, that the Notch activation was essential to form arteries and hematopoietic stem cells. It was also known that the proteins responsible for this activation were ligands Delta4 and Jagged1, respectively. With this study, researchers have shown how this signal works to reach a certain level of activation and form the two different types of cells.

    Més informació "A step forward in obtaining blood stem cells in laboratory"

  • 21/09/2015 - Press release

    Novel gene implicated in osteoporosis

    An uncommon variant of the gene EN1 contributes to bone mineral density and osteoporotic fractures, according to a study recently published in the journal Nature. Daniel Grinberg, expert in the Department of Genetics of the University of Barcelona (UB) and member of the Institute of Biomedicine of the UB (IBUB), has participated in the study. Xavier Nogués and Natàlia Garcia Giralt, experts at the Service of Internal Medicine of the Hospital del Mar and the Hospital del Mar Medical Research Institute (IMIM) also participate in the study, which is led by Brent Richards, professor at McGill University (Montreal, Canada). The study is also part of a research line on bone pathologies developed by the Centre for Biomedical Network Research on Rare Diseases (CIBERER), led by professors Daniel Grinberg and Susana Balcells (Department of Genetics of the UB and IBUB) with the collaboration of experts on internal medicine from the Hospital del Mar and the IMIM.  

    Més informació "Novel gene implicated in osteoporosis"

  • 07/09/2015 - Press release

    New clues on the genetic basis of myocardial infarction

    The CARDIoGRAMplusC4D Consortium, an international project in which researchers from theIMIM (Hospital del Mar Medial Research Institute) participated as the only Spanish participants, has identified 58 DNA loci or regions, 10 of which are new, linked to the risk of experiencing an ischemic heart disease. These 58 loci, besides confirming the relevance of controlling cholesterol levels and inflammation, identify in a novel way the relevance of the functioning of the arterial wall in the origin of this disease. The study is published in the prestigious journal Nature Genetics and is the first to have systematically analysed 2.7 million rare genetic characteristics. Ischemic heart disease is the leading cause of death in industrialised countries and can appear as an angina pectoris, a myocardial infarction and, sometimes, as sudden death. It is known that genetic factors account for 40 to 50% of the risk of suffering the disease, and this explains why great efforts are being invested to identify the genetic characteristics associated to this pathology, after 48 genetic characteristics have been identified in previous studies, some of which by this same research group.

    Més informació "New clues on the genetic basis of myocardial infarction"

  • 18/05/2015 - Press release

    3.5 million euros to develop bioinformatics tools that facilitate translational research and personalized medicine in oncology and neuropsychiatry

    Under Horizon 2020, the EU has funded the 3.5 million project MedBioinformatics. This project aims to develop useful bioinformatics tools and applications, and autonomously usable for analysing the huge amount of data and knowledge generated in healthcare and biomedical research in order to facilitate translational research and precision medicine.The Hospital del Mar Medical Research Institute of Barcelona (IMIM) coordinates the EU-funded MedBioinformatics research project. According to Prof. Ferran Sanz, director of the IMIM-UPF Research Programme on Biomedical Informatics (GRIB) and coordinator of this project, "most potential users, i.e. translational researchers and health professionals, do not have adequate tools to efficiently exploit this large and heterogeneous amount of information. So far, efforts to develop bioinformatics methods and tools have not produced the expected impact in healthcare environments"

    Més informació "3.5 million euros to develop bioinformatics tools that facilitate translational research and personalized medicine in oncology and neuropsychiatry"

  • 13/05/2015 - Press release

    Key role of enzyme in the pluripotency of embryonic stem cells discovered

    Researchers from the Hospital del Mar Medical Research Institute (IMIM) have discovered the key role of an enzyme in the differentiation ability of embryonic stem cells. According to the study published in the journal Molecular Cell, enzyme LOXL2 would be involved in maintaining the balance between the pluripotency and the differentiation in this type of cells that can turn into any cell in the body. The study was coordinated by the researcher from the Cancer Research Programme Sandra Peiró, and explores in greater depth the knowledge on the specialization mechanism of embryonic stem cells, opening the door to a better manipulation. Researchers from the Experimental and Health Sciences Department at the Universitat Pompeu Fabra also participated in the study.

    Més informació "Key role of enzyme in the pluripotency of embryonic stem cells discovered"

  • 28/04/2015 - Press release

    Chemotargets launches easier-to-use, more intuitive graphical interface CTlink[GUI]

    Chemotargets, a spin-off company of IMIM, has launched CTlink[GUI] - a commercial version of the CTlink software that offers users intuitive, interactive graphical tools enabling them to more easily analyse results obtained using this software. CTlink can be installed on any Linux, Windows or Mac computer, desktop or laptop, and can predict how a small molecule will interact with thousands of different proteins. It is designed as a computational framework for linking different systemic entities - that is, for linking molecules, proteins, pathways, side effects, organs and diseases. It is a very important tool used by biotechnology and pharmaceutical companies. 

    Més informació "Chemotargets launches easier-to-use, more intuitive graphical interface CTlink[GUI]"

Contact

Head of Communications:
Rosa Manaut(ELIMINAR)

Communications office:
Marta Calsina(ELIMINAR)

Tel:
(+34) 93 316 06 80
(+34) 699 094 833

Doctor Aiguader, 88
08003 Barcelona

© Institut Hospital del Mar
d'Investigacions Mèdiques
Legal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact